Stanton Gerson has a long-standing interest in mesenchymal and hematopoietic stem cells, and stem cell gene transfer. His research focuses on several different model systems evaluating the role of DNA repair in stem cells, mesenchymal stem cells (MSC) and the use of these two stem cell classes for hematopoietic tissue regeneration and reconstitution. In one relatively mature project, now in phase 2 clinical trials, his goal is to evaluate the transduction of drug resistance to hematopoietic stem cells in patients undergoing chemotherapy for the treatment of glioma. Another area of research focuses on improvements in expression transduction of multi lineage progeny populations. Such advances would lead to improved therapeutics. Gerson also directs a center with a clinical cell production facility capable of producing stem cells under academic GMP-like processes. He has extensive experience with FDA IND applications and can assist a variety of projects in bringing stem cells from the laboratory toward the clinic.
- Stan Gerson, MD
- Institution: Case Western Reserve University
- Distinguished University Professor, Director of the Case Comprehensive Cancer Center and the National Center for Regenerative Medicine
- Research Interests: Stem cells and DNA repair, stem cell treatments for hematologic malignancies